Table 1.
Study Population
| ID# | Progression* | Sex | Age | Stage | TNMB |
|---|---|---|---|---|---|
|
| |||||
| 1 | No | F | 67 | IB | T2bN0B0xM0 |
| 2 | No | M | 62 | IB | T2bN0B0xM0 |
| 3 | No | M | 51 | IA | T1bN0B0xM0 |
| 4 | No | M | 68 | IB | T2bN0B0xM0 |
| 5 | No | M | 65 | IIA | T2bN1xB0aM0 |
| 6 | No | F | 76 | IB | T2bN0B0xM0 |
| 7 | No | M | 81 | IIA | T2bNXB0xM0 |
| 8 | No | F | 68 | IB | T2bN0B0bM0 |
| 9 | No | M | 53 | IB | T2bN0B0aM0 |
| 10 | No | M | 66 | IB | T2bN0B0xM0 |
| 11 | Yes | M | 65 | IB | T2bN0B0xM0 |
| 12 | Yes | F | 40 | IB | T2bN0B0aM0 |
| 13 | Yes | M | 58 | IIA | T2bN1aB0aM0 |
| 14 | Yes | F | 69 | IIA | T2bN0B0xM0 |
| 15 | Yes | F | 67 | IIA | T2bN1aB0xM0 |
| 16 | Yes | M | 65 | IB | T2bN0B0xM0 |
| 17 | Yes | M | 49 | IA | T1bN0B0xM0 |
| 18 | Yes | F | 32 | IB | T2bN0B1aM0 |
*
Defined as increasing in disease stage over the course of follow-up (median 44.5 months); M= male; F= female.